Zacks Research Issues Pessimistic Outlook for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research cut their Q1 2027 earnings estimates for shares of Prestige Consumer Healthcare in a research report issued on Tuesday, February 24th. Zacks Research analyst Team now expects that the company will earn $1.09 per share for the quarter, down from their prior forecast of $1.24. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2027 earnings at $4.77 EPS, Q2 2028 earnings at $1.30 EPS, Q3 2028 earnings at $1.26 EPS and FY2028 earnings at $5.06 EPS.

PBH has been the subject of a number of other research reports. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Jefferies Financial Group decreased their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $70.26 on Friday. The firm has a market capitalization of $3.32 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 2.18 and a beta of 0.43. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. The business’s 50-day moving average price is $65.11 and its 200-day moving average price is $63.45. Prestige Consumer Healthcare has a 12 month low of $57.25 and a 12 month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period in the previous year, the firm posted $1.22 EPS. The business’s quarterly revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently bought and sold shares of the company. UMB Bank n.a. raised its position in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after acquiring an additional 219 shares in the last quarter. Bayforest Capital Ltd bought a new stake in Prestige Consumer Healthcare in the fourth quarter worth approximately $29,000. First Horizon Corp acquired a new position in Prestige Consumer Healthcare in the third quarter valued at approximately $32,000. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after buying an additional 269 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

More Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group disclosed a new stake in PBH (10,912 shares, about $681,000), signaling some institutional buying interest that can provide support to the stock. Article Title
• Neutral Sentiment: Zacks Research left a “Hold” rating and kept the consensus full?year EPS near $4.50; a few quarterly estimates were nudged higher (Q4 2026 to $1.59, Q4 2027 to $1.32, Q3 2027 to $1.21), indicating mixed views rather than a clear upgrade.
• Negative Sentiment: Zacks cut multiple near?term estimates, hitting Q1 2027 hardest (from $1.24 to $1.09) and trimming Q1 2028 (1.26?1.14), Q2 2028 (1.33?1.30), Q3 2028 (1.28?1.26), FY2027 (4.84?4.77) and FY2028 (5.19?5.06). Those downward revisions lower near?term earnings expectations and are the main reason sentiment is weakening today.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).